As of March 2024, the FDA-approved medication Rezdiffra (resmetirom) is the first drug to treat liver scarring caused by nonalcoholic fatty liver disease (NAFLD) in adults. Rezdiffra is a daily pill that targets a protein in the liver to reduce inflammation, fat, and scarring. Clinical trials have shown that Rezdiffra can stop or even reverse fibrosis progression. In one study, 26% of patients at the lower dose and 30% at the higher dose resolved NASH without worsening fibrosis, and 24% and 26% of patients, respectively, improved fibrosis by at least one stage. Rezdiffra is intended to be used in conjunction with diet and exercise